Pathogenic alterations, namely, fusions and amplifications, of the GLI1 gene have been identified in various mesenchymal tumors, including pericytoma with t(7;12), plexiform fibromyxoma, gastroblastoma, and other malignant mesenchymal neoplasms arising in the soft tissues, as well as in various visceral organs. However, only three cases of GLI1-rearranged renal tumors have been reported to date, comprising two low-grade spindle cell tumors with GLI1::FOXO4 fusion along with one GLI1-rearranged case with an unknown fusion partner. In this study, we analyzed three cases with GLI1::FOXO4 fusion and overlapping morphology. One of the cases was reported previously, but an extended clinical and immunohistochemical information is provided. The studied cases occurred in 2 female and 1 male patients aged 35, 55, and 62 years (mean 51 years). All three tumors affected the renal parenchyma and grew as unencapsulated but well-circumscribed solid masses containing occasional entrapped and dilated renal tubules. The tumor cells were organized in cords, nests, or fascicles, had a round to spindled shape, and exhibited only mild nuclear atypia and minimal mitotic activity. They had a sparse eosinophilic to clear cytoplasm and were embedded in myxocollagenous stroma. Immunohistochemically, all cases expressed GLI1 (albeit with variable intensity) and harbored GLI1::FOXO4 fusion. All three patients were treated solely by complete surgical excision. Case 1 was alive with unknown disease status, case 2 was alive without evidence of disease, and case 3 died of unrelated causes. Our study doubles the number of reported cases with GLI1::FOXO4 fusion. The so far absolute predilection of this fusion for renal tumors, coupled with the absence of reports of other GLI1 fusions in tumors of the kidney, might indicate the potential existence of a distinct renal subtype with morphological features similar to other GLI1-altered tumors. All four reported cases had an uneventful follow-up which, together with their low-grade morphological features, suggests that these tumors might have a favorable prognosis.

Bioptical Laboratory Ltd Plzen Czech Republic

Dartmouth Hitchcock Medical Center Geisel School of Medicine at Dartmouth Hanover NH USA

Department of Pathology and Laboratory Medicine Memorial Sloan Kettering Cancer Center New York NY USA

Department of Pathology Charles University Faculty of Medicine in Plzen Plzen Czech Republic

Department of Pathology Laboratoře Agel Ltd Nový Jičín Czech Republic

Pathology Department Instituto Valenciano de Oncología and Patologika Laboratory Hospital Quirón Salud Valencia Spain

Zobrazit více v PubMed

Graham RP, Nair AA, Davila JI et al (2017) Gastroblastoma harbors a recurrent somatic MALAT1-GLI1 fusion gene. Mod Pathol 30:1443–1452 PubMed DOI

Spans L, Fletcher CD, Antonescu CR et al (2016) Recurrent MALAT1-GLI1 oncogenic fusion and GLI1 up-regulation define a subset of plexiform fibromyxoma. J Pathol 239:335–343 PubMed DOI PMC

WHO Classification of Tumours Editorial Board. Digestive system tumours. Lyon (France): International Agency for Research on Cancer; 2019. (WHO classification of tumours series, 5th ed.; vol. 1). https://publications.iarc.fr/579 .

WHO Classification of Tumours Editorial Board. Head and neck tumours. Lyon (France): International Agency for Research on Cancer; 2023. (WHO classification of tumours series, 5th ed.; vol. 9). https://publications.iarc.who.int/629 .

Agaram NP, Zhang L, Sung YS et al (2019) GLI1-amplifications expand the spectrum of soft tissue neoplasms defined by GLI1 gene fusions. Mod Pathol 32:1617–1626 PubMed DOI PMC

Saoud C, Agaimy A, Dermawan JK et al. (2024) A comprehensive clinicopathologic and molecular reappraisal of GLI1-altered mesenchymal tumors with pooled outcome analysis showing poor survival in GLI1- amplified versus GLI1-rearranged tumors. Am J Surg Pathol 48:1302-1317

Kerr DA, Pinto A, Subhawong TK et al (2019) Pericytoma with t(7;12) and ACTB-GLI1 fusion: reevaluation of an unusual entity and its relationship to the spectrum of GLI1 fusion-related neoplasms. Am J Surg Pathol 43:1682–1692 PubMed DOI PMC

Pettus JR, Kerr DA, Stan RV et al (2021) Primary myxoid and epithelioid mesenchymal tumor of the kidney with a novel GLI1-FOXO4 fusion. Genes Chromosomes Cancer 60:116–122 PubMed DOI

Argani P, Boyraz B, Oliva E et al (2022) GLI1 gene alterations in neoplasms of the genitourinary and gynecologic tract. Am J Surg Pathol 46:677–687 PubMed DOI PMC

Machado I, Agaimy A, Giner F et al (2024) The value of GLI1 and p16 immunohistochemistry in the premolecular screening for GLI1-altered mesenchymal neoplasms. Virchows Arch 484:765–775 PubMed DOI

Warmke LM, Michal M, Martinek P et al (2023) “PRRX1-rearranged mesenchymal tumors”: expanding the immunohistochemical profile and molecular spectrum of a recently described entity with the proposed revision of nomenclature. Virchows Arch 483:207–214 PubMed DOI

Parrack PH, Marino-Enriquez A, Fletcher CDM, Hornick JL, Papke DJ Jr (2023) GLI1 immunohistochemistry distinguishes mesenchymal neoplasms with GLI1 alterations from morphologic mimics. Am J Surg Pathol 47:453–460 PubMed DOI

Xu B, Chang K, Folpe AL et al (2020) Head and neck mesenchymal neoplasms with GLI1 gene alterations: a pathologic entity with distinct histologic features and potential for distant metastasis. Am J Surg Pathol 44:729–737 PubMed DOI PMC

Antonescu CR, Agaram NP, Sung YS et al (2018) A distinct malignant epithelioid neoplasm with GLI1 gene rearrangements, frequent S100 protein expression, and metastatic potential: expanding the spectrum of pathologic entities with ACTB/MALAT1/PTCH1-GLI1 fusions. Am J Surg Pathol 42:553–560 PubMed DOI PMC

Cloutier JM, Kerr DA (2024) GLI1-altered mesenchymal tumors. Surg Pathol Clin 17:13–24 PubMed DOI

Argani P, Dickson BC, Gross JM et al (2023) Ossifying fibromyxoid tumor of the genitourinary tract: report of 4 molecularly confirmed cases of a diagnostic pitfall. Am J Surg Pathol 47:709–716 PubMed DOI PMC

Al-Ahmadie HA, Yilmaz A, Olgac S, Reuter VE (2007) Glomus tumor of the kidney: a report of 3 cases involving renal parenchyma and review of the literature. Am J Surg Pathol 31:585–591 PubMed DOI

Argani P, Pawel B, Szabo S, Reyes-Múgica M, Timmons C, Antonescu CR (2018) Diffuse strong BCOR immunoreactivity is a sensitive and specific marker for clear cell sarcoma of the kidney (CCSK) in pediatric renal neoplasia. Am J Surg Pathol 42:1128–1131 PubMed DOI PMC

Argani P, Perlman EJ, Breslow NE, Browning NG, Green DM, D’Angio GJ, Beckwith JB (2000) Clear cell sarcoma of the kidney: a review of 351 cases from the National Wilms Tumor Study Group Pathology Center. Am J Surg Pathol 24:4–18 PubMed DOI

Calio A, Eble JN, Grignon DJ, Delahunt B (2016) Mixed epithelial and stromal tumor of the kidney: a clinicopathologic study of 53 cases. Am J Surg Pathol 40:1538–1549 PubMed DOI

Michal M, Hes O, Bisceglia M et al (2004) Mixed epithelial and stromal tumors of the kidney. A report of 22 cases. Virchows Arch 445:359–367 PubMed DOI

Saoud C, Agaimy A, Dermawan JK, Chen JF, Rosenblum MK, Dickson BC, Dashti N, Michal M, Kosemehmetoglu K, Din NU, Albritton K, Agaram NP, Antonescu CR (2024) A comprehensive clinicopathologic and molecular reappraisal of GLI1 -altered mesenchymal tumors with pooled outcome analysis showing poor survival in GLI1 - amplified versus GLI1- rearranged tumors. Am J Surg Pathol 2024(48):1302–1317 DOI